WO2004020470A1 - システインプロテアーゼ処理コラーゲンの製造方法およびシステインプロテアーゼ処理コラーゲン - Google Patents
システインプロテアーゼ処理コラーゲンの製造方法およびシステインプロテアーゼ処理コラーゲン Download PDFInfo
- Publication number
- WO2004020470A1 WO2004020470A1 PCT/JP2003/002346 JP0302346W WO2004020470A1 WO 2004020470 A1 WO2004020470 A1 WO 2004020470A1 JP 0302346 W JP0302346 W JP 0302346W WO 2004020470 A1 WO2004020470 A1 WO 2004020470A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagen
- cysteine protease
- treated
- atelocollagen
- treated collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- the present invention relates to collagen, a method for producing the same, and uses thereof. Specifically, it relates to cysteine protease-treated collagen, its production method, and its use. Background art
- Collagen which is a main protein constituting connective tissue and bone tissue between cells in animals, is widely used in fields such as cosmetics, food additives and medical materials.
- collagen-containing materials include, for example, food additives; cosmetic materials; solvents for preparing artificial skin, hemostatic sponges, bone reconstituting materials, and soft tissue fillers. Is being applied to medical materials.
- collagen which is widely used at present, is often extracted and purified from dermis or bones of calves and pigs.
- skins such as calves contain hairs and fats, so pretreatment is required to remove them.
- the yield of acid-soluble collagen to be purified is not as high as about 5%.
- Complicated operations may be required in some cases, such as the necessity of a process for removing the causative substances that cause infection and disease among livestock and an analysis process.
- the amount of collagen obtained from one animal was relatively small. For this reason, while maintaining excellent functions, it is possible to apply collagen to biomaterials and the like by a simple method that does not require complicated steps caused by infection between livestock and the like. Appearance was also required.
- the present invention has been made based on the background art as described above, and has excellent biocompatibility, excellent moisturizing effect, excellent hemostatic power, and excellent cell (embryo) culture technology in vitro. It is an object to provide a highly functional collagen having properties and a method for producing the same. Disclosure of the invention
- cysteine protease-treated collagen The collagen obtained by contacting collagen or atelocollagen and cysteine protease (it may be hereafter called “cysteine protease-treated collagen") force Biocompatibility.
- cysteine protease-treated collagen The collagen obtained by contacting collagen or atelocollagen and cysteine protease (it may be hereafter called “cysteine protease-treated collagen") force Biocompatibility.
- cysteine protease-treated collagen Such cysteine protease-treated collagen has a unique network-like aggregate structure, and fibrosis is inhibited.
- the method for producing collagen treated with cysteine protease according to the present invention is characterized by contacting collagen or atelocollagen with cysteine protease.
- the collagen treated with cysteine protease according to the present invention is obtained by contacting collagen or atelocollagen with cysteine protease.
- the collagen or atelocollagen is preferably fish or bird or mammal-derived collagen or atelocollagen, and more preferably fish-derived collagen or atelocollagen.
- the cysteine protease-treated collagen has a triple helical structure in which one cysteine protease-treated collagen molecule is composed of three polypeptide chains, and a network-like aggregate structure is formed by a plurality of cysteine protease-treated collagen molecules.
- the cysteine protease-treated collagen inhibits fibrosis into one fiber by a plurality of cysteine protease-treated collagen molecules.
- the temperature at which the cysteine protease-treated collagen is denatured by heat is preferably 25 ° C. or higher.
- the cosmetic according to the present invention is characterized by containing the cysteine protease-treated collagen.
- the medical material according to the present invention is characterized by containing the cysteine protease-treated collagen.
- the food additive according to the present invention is characterized by containing the cysteine protease-treated collagen.
- the culture material for cells, tissues or embryos according to the present invention is characterized in that it contains the cysteine protease-treated collagen.
- FIG. 1 is a photograph showing an example of an electron micrograph image (60,000 times, 50 mmol ZL acetate buffer, H 4.0) of atelocollagen.
- FIG. 2 is a photograph showing an example of an electron micrograph image (60,000 times, 50 mmol / L acetate buffer, H 4.0) of cysteine protease-treated collagen.
- FIG. 3 is a photograph showing an example of an electron micrograph image (40,000 times) of gelatin.
- FIG. 4 is a schematic diagram showing an example of type I collagen that forms fibers existing between cells and type IV collagen that exists near the cell membrane. In FIG. 4, 1 indicates cells, 2 indicates cells, 3 indicates type I collagen, and 4 indicates type IV collagen.
- FIG. 5 is a photograph showing the results of analysis of purified cysteine protease-treated collagen by 7.5% SDS polyacrylamide gel electrophoresis.
- FIG. 6 is a chart showing peaks of ⁇ 1 and ⁇ 2 components of cysteine protease-treated collagen and ⁇ 1 and a2 components of atelocollagen measured by cation exchange chromatography.
- Figure 7 shows the optical microscope of the collagen-containing solution treated with cysteine protease after air drying. It is a photograph by a mirror. (Magnification: 100 times)
- FIG. 8 is a photograph taken by an optical microscope after the air-collagen-containing solution is air-dried. (Magnification: 100 times)
- FIG. 9 is a photograph showing an example of an electron micrograph image (60,000-fold, 50 mmol ZL phosphate buffer, H7.4) of cysteine protease-treated collagen.
- FIG. 10 is a photograph showing an example of an electron micrograph image (60,000 times, 50 mmol / L phosphate buffer, ⁇ 7.4) of atelocollagen.
- FIG. 11 is a graph showing the relative solubilities of atelocollagen and cysteine protease-treated collagen in ethanol.
- FIG. 12 is a photograph showing the results of 5% SDS-polyacrylamide gel electrophoresis of atelocollagen and its cysteine protease-treated collagen from the tail of the rabbit's ear.
- FIG. 13 is a photograph showing the results of 5% SDS-polyacrylamide gel electrophoresis of chicken cartilage-derived atelocollagen and its cysteine protease-treated collagen.
- the cysteine protease-treated collagen according to the present invention (hereinafter sometimes referred to as “CP-collagen”) can be obtained by contacting collagen or atelocollagen with cystine protease.
- the collagen used in the present invention includes, for example, mammals such as sea lions, pigs, and egrets, birds such as chickens, animal dermis, tendons, bones, fascia, etc., and fish such as sharks, koi, and tuna. Collagen derived from the skin, scales and the like.
- the atelocollagen used in the present invention includes, for example, dermis, tendons, bones, and fascia of animals such as mammals such as horses, pigs, and egrets, and birds such as chickens.
- Atelocollagen which uses collagen-rich tissue such as fish skin and scales such as shark, carp and tuna as raw materials, and removes the telopeptide region at the amino-terminal and carboxyl-terminal of the molecule with pepsin etc. Is mentioned.
- fish-derived collagen or atelocollagen can be preferably used.
- atrate collagen can be preferably used.
- tuna such as yellowfin tuna, carp, and eel are mentioned, and of these, tuna can be more preferably used.
- telocollagen those having a heat denaturation temperature of preferably 20 ° C. or higher, more preferably 25 ° C. or higher are desirable.
- tuna such as yellowfin tuna and atelocollagen such as carp
- the denaturation temperature of cysteine protease-treated collagen can be adjusted to preferably 20 ° C. or higher, more preferably 25 ° C. or higher, by using such a substance. It is possible to obtain collagen whose denaturation temperature is significantly higher than the denaturation temperature of collagen (about 20 ° C). Therefore, atelocollagen derived from tuna is excellent in storage stability and utility value. Furthermore, in the case of a mug, it is possible to obtain a large amount and uniform performance of cysteine protease-treated atelocollagen in a large amount and with uniform performance due to the large catches and uniformity of the catching period.
- the atelocollagen used in the present invention is usually one fibrous association with atelocollagen molecules, as shown in the photograph taken with an electron microscope (600,000 magnification) in FIG. It is a fibrillated atelocollagen that forms a coalescence, with little intermolecular space.
- the atelocollagen molecule is a portion having a stripe pattern in an electron microscope image.
- the atelocollagen is usually composed of various components, and the composition ratio thereof is not limited because it differs depending on the raw material of the atelocollagen.
- Such atelocollagen usually contains at least four kinds of components, i.e., ⁇ 2 components, i.e. and gamma component.
- the constituent unit of the triple helix structure, ⁇ 1 component and 2 components are both single-stranded left-handed spirals, have different molecular weights, and ⁇ component has two ⁇ components covalently bonded between molecules.
- the ⁇ component is a component of a dimer structure
- the ⁇ component is a component of a trimeric structure in which three ⁇ components are covalently bonded between molecules.
- these components of the atelocollagen molecule form a right-handed triple helical structure.
- the molecular weight of the ⁇ component is usually preferably 90,000 to 130,000, the molecular weight of the component is usually 180,000 to 260,000, and the molecular weight of the ⁇ component is usually 270,000 to 390,000. 000 is desirable.
- Each component can be easily separated by a known method such as electrophoresis.
- the collagen or atelocollagen used in the present invention is usually insoluble in a neutral ⁇ aqueous solution.
- Such collagen or atelocollagen can be extracted from animals or fish by a known method.
- a tissue rich in collagen such as the dermis, tendons, bones, and fascia of the mammal, bird or fish, is put into an acidic solution of about ⁇ ⁇ 2 to 4, eluted, and pepsin is added thereto to add Remove the telopeptide region.
- a salt such as sodium chloride is added to the acidic solution of atelocollagen to obtain a precipitate containing atelocollagen.
- cysteine protease that can be used in the present invention is a known cystine protease, and the type thereof is not particularly limited. Among them, for example, cysteine protease has a larger amount of acidic amino acids than a basic amino acid. Among them, those which are active at the hydrogen ion concentration in the acidic region can be preferably used.
- Acti-Dyne enables effective contact reaction, especially with atelocollagen derived from tuna, and significantly reduces or substantially reduces the content of i3 component and ⁇ component contained in the resulting cysteine protease-treated collagen. ] 3, ⁇ / component can be removed. As a result, it is possible to obtain uniform cysteine protease-treated collagen with a large amount of ⁇ component and high purity. It is also presumed that the covalent bond between the components of the cysteine protease-treated collagen molecule is lacking.
- cysteine proteases can be obtained by known methods, for example, chemical synthesis, extraction from cells or tissues of bacteria and fungi, or various animals and plants, cultured cells thereof, and cysteine derived therefrom. It can be obtained from recombinant protein of protease by genetic engineering means.
- the cysteine protease-treated collagen according to the present invention can be obtained by contacting the collagen or atelocollagen with the cysteine protease.
- the contact between the cysteine protease and collagen or atelocollagen can be performed in a solvent.
- a solvent for example, water can be used as the solvent.
- the amount of the solvent is preferably in the range of 1 to 1000 parts by mass with respect to 1 part by mass of collagen or atelocollagen.
- the amount of cysteine protease used for the contact is preferably 0.1 to 10 parts by mass, more preferably 0.5 to 5 parts by mass, based on 100 parts by mass of collagen or atelocollagen.
- the conditions for contacting the cysteine protease with collagen or atelocollagen are not limited to pH, temperature, and treatment time, and the contact can be carried out in the same manner as a normal enzyme treatment.
- pH is preferably 2. It is desirable to carry out in the range of 0 to 7.0, more preferably in the range of 3.0 to 5.0. In order to keep the pH constant, it is preferable to carry out the reaction in a buffer solution. By setting the pH within the above range, collagen or mouth-mouth collagen is uniformly dissolved, and there is an effect that the enzyme reaction proceeds efficiently.
- the contact temperature is, for example, preferably in the range of about 15 to 4 ° C.
- the contact time is, for example, preferably in the range of about 1 hour to 5 days.
- a step of readjusting the pH and a step of inactivating the enzyme may be performed, if necessary. Further, a purification step for removing impurities may be performed.
- a purification step for removing impurities may be performed.
- the cysteine protease-treated collagen thus obtained preferably has a triple helical structure in which one cysteine protease-treated collagen molecule is composed of three polypeptide chains, and is formed into a network by a plurality of cysteine protease-treated collagen molecules. It is desirable that an aggregate structure is formed.
- the cysteine protease-treated collagen of the present invention preferably inhibits fibrosis into a single fiber by a plurality of cysteine protease-treated collagen molecules, and preferably has a fibrous form such as the atelocollagen. Has substantially no aggregate structure.
- Such cysteine protease-treated collagen has a stable three-dimensional network structure irrespective of changes in pH.
- network refers to a structure in which molecules are connected to form a three-dimensional network by chemical bonding or Van der Waals bonding, and a gap is formed therebetween.
- an association is defined as a case where the same kind of molecule is not formed by a covalent bond. More than one molecule interacts and binds to form one structural unit.
- FIG. 2 is an electron micrograph (6000 ⁇ magnification) showing an example of the cysteine protease-treated collagen of the present invention.
- the collagen of the cysteine protease-treated collagen of the present invention is a thin filamentous molecule. Is a structure that shows a three-dimensional network-like aggregate formed by irregularly binding, similar to collagen called fabril (Fabril associated collagens with interrupted triple helix), which inhibits the fibrosis of the three-dimensional structure.
- the structure is similar to the type IV collagen present in the basement membrane morphologically, that is, it has many spatial gaps.
- the fact that collagen has a triple helical structure can be easily confirmed by a known method, for example, a circularly polarized two-color spectrum.
- the raw material atelocollagen is fibrotic atelocollagen in which atherocollagen molecules form a single fibrous aggregate, and the intermolecular space There is almost no.
- the cysteine protease-treated collagen according to the present invention has a high water retention effect because water molecules are easily taken into the gaps between the cysteine protease-treated collagen, and also has an excellent hemostatic effect because it is easy to take in cells such as red blood cells and platelets. In addition, it has a unique property that it is highly effective as a material for culturing various cells and embryos in vitro.
- type IV collagen 4 that forms a fiber such as the above-mentioned atelocollagen in the center between cells In the vicinity of the basement membrane between cells, type IV collagen 4 having a three-dimensional structure that does not form a fiber aggregate is present.
- a method for extracting type I collagen from intercellular matrix has been established, but according to a study by the present inventors, it has a network-like aggregate structure like type IV collagen and inhibits fibrosis.
- An effective preparation method has not been established for the collagen thus prepared, and the present invention is extremely useful as a means for easily providing a novel type IV collagen-like aggregate.
- the cysteine protease-treated collagen according to the present invention contains ⁇ components such as ⁇ ⁇ component and ⁇ 2 component as components, and does not substantially contain i3 component and ⁇ component.
- the molecular weight of the al and a2 components is preferably 90,000 to 130,000.
- the cysteine protease-treated collagen according to the present invention is preferably dissolved in a neutral ⁇ aqueous solution. This is significantly different from the fact that the raw material aterocollagen is insoluble in neutral ⁇ aqueous solution, and that various collagens including natural fasit ⁇ type IV collagen are insoluble in neutral ⁇ aqueous solution. This is very different.
- the cysteine protease-treated collagen according to the present invention usually has a triple helical structure due to heat denaturation, but does not gel. This is very different from the fact that collagen generally undergoes thermal transformation into gelatin (having a triple helical structure) and gels when cooled. In addition, as shown in an electron micrograph ( ⁇ 40000) showing an example of the structure of gelatin in FIG. 3, the fibrous structure or network structure of gelatin has collapsed.
- collagen containing natural fasit and type IV collagen are different from the cysteine protease-treated collagen according to the present invention.
- the ⁇ 1 component and the ct2 component of the cysteine protease-treated collagen according to the present invention are different in surface charge of each ⁇ component from those of the natural atelocollagen as a raw material. I have. For example, as shown in FIG.
- the ⁇ 1 component and the ⁇ 2 component of the cysteine protease-treated collagen according to the present invention usually give a total of four peaks by cation exchange chromatography, and ⁇ alpha 1 terrorist in collagen, alpha 2 component is usually given a total of six peaks, elution time of these peaks are all different. Therefore, it can be inferred that the surface charges are different.
- cysteine protease-treated collagen according to the present invention has remarkably improved solubility in alcohol such as ethanol as compared with atelocollagen. For this reason, it has excellent solubility in cosmetics and the like to which ethanol is added, and it is possible to add cysteine protease-treated collagen at a high concentration.
- cysteine protease-treated collagen of the present invention is a raw material. It has properties that are not found in collagen or atelocollagen, indicating that the function that is the starting point of interaction with biological materials has been significantly changed.
- the cysteine protease-treated collagen according to the present invention preferably has a denaturation temperature of 25 ° C. or higher, more preferably 28 ° C. or higher, by heat. Therefore, handling at room temperature is easy.
- atelocollagen is derived from fish
- tuna or the like as the raw fish in order to obtain cysteine protease-treated collagen at such a denaturation temperature.
- the cysteine protease-treated collagen of the present invention can be crosslinked and used as polymerized cysteine protease-treated collagen.
- the crosslinking treatment can be performed by a conventionally known method.
- Examples of the method include a method using chemical crosslinking, a method of crosslinking by heat treatment, and a method of crosslinking by irradiation with radiation such as ultraviolet rays.
- crosslinking agent used in the chemical crosslinking examples include water-soluble carpoimide compounds such as 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride; epichlorohydrin; diepoxy conjugates such as bisepoxydiethylene glycolone; And the like.
- concentration of the crosslinking agent with respect to cis Tin protease treatment collagen preferably 1 0 one third to one approximately 0 wt%, preferably in the range of. 5 to 4 0 ° C, preferably about 3 to 4 8 hours,
- the cysteine protease-treated collagen of the present invention is irradiated with ultraviolet rays, for example, by an ultraviolet lamp, usually at room temperature for about 3 to 48 hours to obtain crosslinked cysteine protease-treated collagen. Can be done.
- the cysteine protease-treated collagen according to the present invention is heated under reduced pressure, preferably at a temperature of about 110 to 160 ° C., for about 3 to 48 hours, so that the cysteine protease-treated collagen is treated.
- Collagen can be obtained.
- Such cross-linked cysteine protease-treated collagen is resistant to collagenogen. Zinc properties and strength can be improved.
- the collagen treated with cysteine protease according to the present invention has high solubility in alcohol such as ethanol.
- alcohol such as ethanol
- Examples of the type of chemical modification include, for example, Asinorei-Dani, Myristi / Rai-Dani, and polyethylene glycol modification.
- succinylated cystine protease-treated collagen which is an acylation modification, reacts the cystine protease-treated collagen of the present invention with anhydrous succinic acid in a neutral pH solvent such as a phosphate buffer. You can get it. By saccharifying, the solubility of more neutral pH in a solvent can be improved, and the feel when used can be improved.
- the cysteine protease-treated collagen modified with polyethylene glycol can be obtained by reacting with polyethylene dalicol activated with cyanuric chloride.
- the cysteine protease-treated collagen according to the present invention can be suitably used for food additives, medical materials, cosmetic materials, cell or embryo culture materials, and the like.
- the cysteine protease-treated collagen of the present invention can be used in cosmetics because it has excellent moisture uptake performance, a high moisturizing effect, and excellent biocompatibility.
- it can be suitably used by adding to basic cosmetics and the like.
- a cosmetic containing the cysteine protease-treated collagen of the present invention to inflamed skin, symptoms can be reduced.
- the cysteine protease-treated collagen of the present invention has a high uptake performance of red blood cells and platelets, has a high hemostatic effect, and is excellent in biocompatibility, and thus can be suitably used as a medical material.
- the cysteine protease-treated collagen of the present invention is excellent in biocompatibility, has no problem for food use, and can be suitably used as a food additive.
- the cysteine protease-treated collagen of the present invention is expected to have an excellent effect on culturing various cells, tissues or embryos as an extracellular matrix, can be used safely, and can be used as a cell culture stabilizer. It is suitable.
- tissue refers to a living organism that is surrounded by a membrane structure that isolates the outside world, has transit information with self-renewal capability inside, and has an expression mechanism.In a multicellular organism, it is a structural unit of tissue
- tissue refers to a cell population that differentiates in a specific direction and has the same function and morphology
- embryo refers to a multicellular organism at an early stage of ontogeny.
- the cysteine protease-treated collagen according to the present invention has a network structure, is inhibited from fibrosis, has excellent ability to take in water molecules or erythrocytes, and is excellent in biocompatibility. Also, it has excellent moisturizing effect, hemostatic power and cell retention power.
- sodium salt was added and dissolved at a concentration of 2.5 mol / L, left at 4 for 16 hours, and centrifuged at lOXOX g for 30 minutes to collect the precipitate. .
- the mouth-collagen obtained in Preparation Example 1 was dialyzed three times with 4 against 100 volumes of 20 mmol / L citrate buffer (pH 3.0). After dialysis, a cysteine protease (actinidyne) was added to the atelocollagen so that the weight was 1.0 / 0 . The mixture was stirred at a temperature of 20 ° C. for 3 days to obtain a crude product.
- a cysteine protease actinidyne
- the resulting crude product was purified by cation exchange chromatography.
- a TSKgel SP-Toyopearl 650M column (trade name: manufactured by Tosoh Corporation) obtained by equilibrating the crude product with 2 Ommol / L citrate buffer ( ⁇ 3.5) (hereinafter referred to as “ ⁇ solution”) ), And the components that did not adsorb to the gel were washed by flowing 30 A mL of solution A.
- 2 Ommol / L citrate buffer containing 1.5 mol / L sodium chloride pH 3.5
- the ⁇ 1, a2 components fractionated from the atelocollagen prepared in Preparation Example 1 and the purified cysteine protease-treated collagen were measured by cation chromatography.
- the ⁇ 1 component and ⁇ 2 component contained in the atelocollagen usually give six peaks by cation chromatography or the like, whereas the cysteine proteinase-treated collagen according to the present invention usually has four peaks. Only one peak was given, and the elution times of atelocollagen and the ⁇ component of cysteine protease-treated collagen were all different.
- the atelocollagen (FIG. 1) formed a typical fibrous aggregate structure in which the triple helical structure was regularly arranged, whereas the cysteine protease-treated collagen according to the present invention (FIG. 2). ) was confirmed to have an irregular, mesh-like aggregate structure with many gaps.
- Atelocollagen and cysteine protease-treated collagen were separately dissolved in 5 O mmol / L acetate buffer (pH 4.0), and 1 O / z L was dropped on the slide glass. Leave to dry for 6 hours. Each dried sample was analyzed with an optical biological microscope (manufactured by Shimadzu Corporation). As a result, it was confirmed that the collagen treated with cystine protease (FIG. 7) exhibited a finer pattern than the atelocollagen (FIG. 8). In addition, when the viscosity of each was analyzed by surface tension (droplet weight method), it was confirmed that collagen treated with cysteine protease had higher viscosity than atelocollagen.
- a 10-week-old Os Wistar rat was anesthetized with ether, anesthetized by intraperitoneal administration of chloral hydrate, the tip of the spleen was partially removed, and bleeding was performed with a 18-G needle.
- Cysteine protease-treated collagen and atelocora at bleeding sites Each gen was placed and the bleeding stopped.
- the average time required for hemostasis in each test group was 86 seconds for atelocollagen, 39 seconds for cysteine protease-treated collagen, and 91 seconds for collagen hemostat (commercially available).
- FIGS. 9 and 10 show photographs of each dialysis solution obtained by treating cysteine protease-treated collagen and atelocollagen self-aggregate with different pH buffer solutions. From the electron micrographs of FIGS. 1, 2, 9, and 10, it was confirmed that the atelocollagen self-aggregate forms a fibrous structure even when the pH (4.0 to 7.4) is different. It was confirmed that the collagen treated with cysteine protease did not form a fibrous structure in this pH range but formed a three-dimensional network structure.
- Ethanol was added to each of the cysteine protease-treated collagen solution and the atelocollagen solution to a final concentration of 0, 10, 15, 20, 40, 60, 80% (VV) and mixed. After leaving at 4 for 1 hour, the supernatant was separated by centrifugation at 10,000 g for 30 minutes. The concentration of collagen contained in the supernatant was determined by measuring the absorbance at 21 O nm.
- the relative ratio (%) of the absorbance at each ethanol concentration was calculated with the absorbance at 210 nm of the cysteine protease-treated collagen supernatant solution and the atherocollagen solution at 0% ethanol concentration as 100%. That is, here, the relative ratio is expressed as being directly proportional to the solubility.
- Figure 11 shows the results.
- the relative ratio of atelocollagen solution was 15% at 15% ethanol concentration, but the relative ratio of cysteine protease treated at the same ethanol concentration was 100%. It was confirmed that the solubility of collagen at 0% and 15% ethanol concentration did not change. In addition, the relative ratio at 20% ethanol concentration was only 6% for atelocollagen but 80% for cysteine protease-treated collagen. The ethanol concentration giving 50% solubility showed a difference of about 10% between atelocollagen and cysteine protease-treated collagen.
- high solubility in ethanol has the following advantages. That is, for example, in cosmetics, ethanol is often added, and the higher the solubility in ethanol, the higher the concentration of cysteine protease-treated collagen can be added. Therefore, cysteine protease-treated collagen The effect of the addition can be further enhanced.
- cysteine protease-treated collagen according to the present invention has high solubility in ethanol even without special chemical modification as described above, and there is no fear of deterioration in properties due to the chemical modification.
- cysteine protease-treated collagen is modified by acylation to ethanol. It is also possible to increase the solvability, in which case it is presumed that the higher the concentration, the smoother the touch, the less powdery and the more effective cosmetics.
- the cysteine protease-treated collagen has a high solubility, it is possible to prepare a sample by uniformly dispersing it even in a high-concentration aqueous ethanol solution. Therefore, it can be used in various fields. Furthermore, by adding cystine protease-treated collagen to ethanol and evaporating the solvent, a uniformly dispersed solid can be obtained. This can be used for forming a multilayer film. Amount of water evaporation of collagen
- Atelocollagen 0.5% atelocollagen solution dissolved in 20 mmol / L acetate buffer (pH 4.0)
- one 24-well plastic plate (Libro, manufactured by ICN) with a 16-mm diameter (2.0 mm 2 ) was prepared, and the weight (tare) was measured.
- Each plate was placed in an incubator at 22 ° C and a humidity of 50% to 60%, and was left as it was for 11 hours, 13 hours, 14 hours, 18 hours, 22 hours, 30 hours, and 37 hours.
- the weight of each plate was measured with an electronic balance, the tare weight and the protein concentration were measured, and the amount of water evaporation was determined.
- the protein weight 0.5 mg ZmL was subtracted from the weight of the solution of atelocollagen and cysteine protease-treated collagen (CP collagen) added at 0 hours, and the respective water amounts W (0).
- W (0) force of atelocollagen and cysteine protease-treated collagen Calculate coefficients to be equal to W (0) of S control, correct W (t) at each time with each correction coefficient, and calculate W £ (t). Calculated.
- dW '(t) was calculated by subtracting W (0) from the solution weight W' (t) at each time. Relative ratio of weight change dW '(t) of solution at each time, assuming dW (37) of control weight change after standing for 37 hours as 100%
- atelocollagen showed a gradual decrease in the effect of inhibiting water evaporation from the control, from 6% after 13 hours, and showed little difference from the control after 18 hours. . In other words, the effect of suppressing water evaporation was lost over time.
- cysteine protease-treated collagen showed a 10% reduction in water evaporation compared to the control after 13 hours. Even more surprisingly, this remarkable water evaporation suppression effect was 10.5% even after 22 hours, and it was confirmed for the first time that the water evaporation suppression effect lasted for a long time. From this experimental result, it was clarified that the water retention capacity of cysteine protease-treated collagen was significantly different from that of atelocollagen.
- Eg of the heron 5.45 g and 18.2 g of the tail were each finely chopped, and 10 OmL of an O.lmol / L acetic acid aqueous solution was added, followed by pulverization with a Perling blender. After stirring at 4 ° C. for 3 days, the mixture was centrifuged at 10, OX g for 30 minutes to obtain a primary supernatant of each sample. Further, 10 OmL of a 10 Ommol / L acetic acid aqueous solution was added to the precipitated portion, and the mixture was stirred and centrifuged in the same manner to obtain a secondary supernatant.
- porcine pepsin manufactured by Cygnet
- bovine pepsin manufactured by Cygnet
- the precipitate was collected with care.
- a part of the atelocollagen of the egret ears and tail obtained in Preparation Example 2 was transferred to separate containers each having a lid.
- Cysteine protease (acti-dyne) was activated at 25 ° C. for 1 hour in a 2 O mmol / L phosphate buffer (pH 6.5) containing 5 mmol / L dithiothreitol and 1 mmol / LEDTA. To each atelocollagen sample solution was added 3.0% (w / v) activated actinidyne. The mixture was stirred at 20 ° C for 7 days to obtain a crude product.
- the prepared herring-derived cysteine protease-treated collagen (ear-derived and tail-derived) and acti-dyne were separated and purified by a patch method using an anion exchange gel. Specifically, an appropriate amount of TSKgel DEAE-Toyopearl 650C gel (manufactured by Tosoh Corporation) equilibrated with 20 mmol / L acetate buffer (pH 4.0) was added to the crude enzyme reaction product,
- the crude product was analyzed by 5% SDS polyacrylamide gel electrophoresis.As a result, as shown in FIG. 12, the obtained cystine protease-treated collagen derived from egrets had a molecular weight of only 100,000 It was confirmed that it consisted of only components.
- the purified cystine protease-treated collagen from the perforated ears and tail obtained was dialyzed three times against distilled water and then lyophilized.
- the collagen-treated cysteine-mouth-tease-treated collagen and actinidain prepared as described above were separated and purified by a column method using an anion exchange gel.
- the crude product of the enzymatic reaction was passed through a column filled with DEAE-Toyopearl 650C gel (manufactured by Tosoichi Co., Ltd.) to fractionate the CP-collagen derived from E.
- the crude product was analyzed by 5% SDS polyacrylamide gel electrophoresis. As a result, it was confirmed that the crude product consisted of only the ⁇ - chain component having a molecular weight of about 100,000 without the J3 and ⁇ chains.
- the cysteine protease (acti-dyne) activated as described above was added to the chicken atelocollagen solution obtained as described above to a concentration of 3.0% (w / v). The mixture was stirred at 30 ° C for 3 days to obtain a crude product. The crude product was analyzed by 5% SDS-polyacrylamide gel electrophoresis. It has been shown that it has no molecular weight of about 90,000 to 130,000.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004532678A JP4490268B2 (ja) | 2002-08-28 | 2003-02-28 | システインプロテアーゼ処理コラーゲンの製造方法およびシステインプロテアーゼ処理コラーゲン |
| AU2003211379A AU2003211379A1 (en) | 2002-08-28 | 2003-02-28 | Process for producing collagen treated with cysteine protease and collagen treated with cysteine protease |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002/248696 | 2002-08-28 | ||
| JP2002248696 | 2002-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004020470A1 true WO2004020470A1 (ja) | 2004-03-11 |
Family
ID=31972531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2003/002346 Ceased WO2004020470A1 (ja) | 2002-08-28 | 2003-02-28 | システインプロテアーゼ処理コラーゲンの製造方法およびシステインプロテアーゼ処理コラーゲン |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP4490268B2 (ja) |
| AU (1) | AU2003211379A1 (ja) |
| WO (1) | WO2004020470A1 (ja) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100875136B1 (ko) | 2008-04-16 | 2008-12-22 | 주식회사 다림바이오텍 | 돼지 유래 에스터화 아텔로콜라겐을 이용한 접착성 지혈제및 그 제조방법 |
| JP2010168292A (ja) * | 2009-01-20 | 2010-08-05 | Kyoei Kagaku Kogyo Kk | 架橋コラーゲン類及び該コラーゲン類を含む化粧料 |
| JP2011526304A (ja) * | 2009-07-27 | 2011-10-06 | 國立成功大學 | 多孔質コラーゲン基質を調製する方法 |
| JP2014514118A (ja) * | 2011-04-28 | 2014-06-19 | ライフセル コーポレーション | 組織製品の酵素処理方法 |
| WO2015167004A1 (ja) * | 2014-04-30 | 2015-11-05 | 学校法人近畿大学 | 分化誘導用組成物 |
| CN105087728A (zh) * | 2015-08-14 | 2015-11-25 | 浙江省海洋开发研究院 | 一种金枪鱼鱼骨胶原蛋白源硒螯合胶原肽的制备方法 |
| CN105087729A (zh) * | 2015-08-14 | 2015-11-25 | 浙江省海洋开发研究院 | 一种金枪鱼鱼骨胶原蛋白肽的制备方法 |
| US9592254B2 (en) | 2013-02-06 | 2017-03-14 | Lifecell Corporation | Methods for localized modification of tissue products |
| WO2017073785A1 (ja) * | 2015-10-30 | 2017-05-04 | 学校法人近畿大学 | 分化誘導剤、分化誘導方法、および、これらに用いられる骨組織分解物の製造方法 |
| WO2017073761A1 (ja) * | 2015-10-28 | 2017-05-04 | 学校法人近畿大学 | 多能性幹細胞の胚様体形成方法および多能性幹細胞の胚様体形成用組成物 |
| US9957477B2 (en) | 2011-04-28 | 2018-05-01 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
| US10207025B2 (en) | 2011-04-28 | 2019-02-19 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
| US10307510B2 (en) | 2013-11-04 | 2019-06-04 | Lifecell Corporation | Methods of removing alpha-galactose |
| US10413634B2 (en) | 2017-01-30 | 2019-09-17 | Lifecell Corporation | Transglutaminase treated products |
| WO2020122198A1 (ja) * | 2018-12-12 | 2020-06-18 | 学校法人近畿大学 | コラーゲン固形物、コラーゲン固形物の製造方法、生体材料、および、生体外材料 |
| US10792394B2 (en) | 2016-06-03 | 2020-10-06 | Lifecell Corporation | Methods for localized modification of tissue products |
| US10940184B2 (en) | 2017-01-30 | 2021-03-09 | Lifecell Corporation | Tissue matrix materials and enzymatic adhesives |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0823979A (ja) * | 1994-07-15 | 1996-01-30 | Terumo Corp | ヒト・コラーゲン発現ベクターおよびヒト・コラーゲンの製造方法 |
| WO1999046588A1 (en) * | 1998-03-12 | 1999-09-16 | Isao Karube | Apparatus for automatically measuring minute membrane potential |
| JP2001026753A (ja) * | 1999-07-14 | 2001-01-30 | Sunstar Inc | 高血圧症予防又は治療用組成物 |
| JP2001031586A (ja) * | 1999-07-14 | 2001-02-06 | Sunstar Inc | 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物 |
| WO2001010903A2 (en) * | 1999-08-09 | 2001-02-15 | Incyte Genomics, Inc. | Proteases and protease inhibitors |
| JP2001055366A (ja) * | 1999-08-12 | 2001-02-27 | Kissei Pharmaceut Co Ltd | ビアリール酢酸アミド誘導体 |
| JP2001089383A (ja) * | 1999-09-14 | 2001-04-03 | Lion Corp | 口腔用及び眼科用組成物 |
| WO2001030772A1 (en) * | 1999-10-26 | 2001-05-03 | Astrazeneca Ab | Compounds and their use as cysteine protease inhibitors |
-
2003
- 2003-02-28 AU AU2003211379A patent/AU2003211379A1/en not_active Abandoned
- 2003-02-28 WO PCT/JP2003/002346 patent/WO2004020470A1/ja not_active Ceased
- 2003-02-28 JP JP2004532678A patent/JP4490268B2/ja not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0823979A (ja) * | 1994-07-15 | 1996-01-30 | Terumo Corp | ヒト・コラーゲン発現ベクターおよびヒト・コラーゲンの製造方法 |
| WO1999046588A1 (en) * | 1998-03-12 | 1999-09-16 | Isao Karube | Apparatus for automatically measuring minute membrane potential |
| JP2001026753A (ja) * | 1999-07-14 | 2001-01-30 | Sunstar Inc | 高血圧症予防又は治療用組成物 |
| JP2001031586A (ja) * | 1999-07-14 | 2001-02-06 | Sunstar Inc | 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物 |
| WO2001010903A2 (en) * | 1999-08-09 | 2001-02-15 | Incyte Genomics, Inc. | Proteases and protease inhibitors |
| JP2001055366A (ja) * | 1999-08-12 | 2001-02-27 | Kissei Pharmaceut Co Ltd | ビアリール酢酸アミド誘導体 |
| JP2001089383A (ja) * | 1999-09-14 | 2001-04-03 | Lion Corp | 口腔用及び眼科用組成物 |
| WO2001030772A1 (en) * | 1999-10-26 | 2001-05-03 | Astrazeneca Ab | Compounds and their use as cysteine protease inhibitors |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100875136B1 (ko) | 2008-04-16 | 2008-12-22 | 주식회사 다림바이오텍 | 돼지 유래 에스터화 아텔로콜라겐을 이용한 접착성 지혈제및 그 제조방법 |
| JP2010168292A (ja) * | 2009-01-20 | 2010-08-05 | Kyoei Kagaku Kogyo Kk | 架橋コラーゲン類及び該コラーゲン類を含む化粧料 |
| JP2011526304A (ja) * | 2009-07-27 | 2011-10-06 | 國立成功大學 | 多孔質コラーゲン基質を調製する方法 |
| US9956316B2 (en) | 2011-04-28 | 2018-05-01 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
| JP2014514118A (ja) * | 2011-04-28 | 2014-06-19 | ライフセル コーポレーション | 組織製品の酵素処理方法 |
| US10207025B2 (en) | 2011-04-28 | 2019-02-19 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
| US9957477B2 (en) | 2011-04-28 | 2018-05-01 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
| US10568988B2 (en) | 2013-02-06 | 2020-02-25 | Lifecell Corporation | Methods for localized modification of tissue products |
| US9592254B2 (en) | 2013-02-06 | 2017-03-14 | Lifecell Corporation | Methods for localized modification of tissue products |
| US10307510B2 (en) | 2013-11-04 | 2019-06-04 | Lifecell Corporation | Methods of removing alpha-galactose |
| JPWO2015167004A1 (ja) * | 2014-04-30 | 2017-04-20 | 学校法人近畿大学 | 分化誘導用組成物 |
| US10155804B2 (en) | 2014-04-30 | 2018-12-18 | Kinki University | Composition for inducing differentiation |
| WO2015167004A1 (ja) * | 2014-04-30 | 2015-11-05 | 学校法人近畿大学 | 分化誘導用組成物 |
| CN105087729A (zh) * | 2015-08-14 | 2015-11-25 | 浙江省海洋开发研究院 | 一种金枪鱼鱼骨胶原蛋白肽的制备方法 |
| CN105087728A (zh) * | 2015-08-14 | 2015-11-25 | 浙江省海洋开发研究院 | 一种金枪鱼鱼骨胶原蛋白源硒螯合胶原肽的制备方法 |
| JPWO2017073761A1 (ja) * | 2015-10-28 | 2018-08-23 | 学校法人近畿大学 | 多能性幹細胞の胚様体形成方法および多能性幹細胞の胚様体形成用組成物 |
| WO2017073761A1 (ja) * | 2015-10-28 | 2017-05-04 | 学校法人近畿大学 | 多能性幹細胞の胚様体形成方法および多能性幹細胞の胚様体形成用組成物 |
| JPWO2017073785A1 (ja) * | 2015-10-30 | 2018-08-16 | 学校法人近畿大学 | 分化誘導剤、分化誘導方法、および、これらに用いられる骨組織分解物の製造方法 |
| JP6991570B2 (ja) | 2015-10-30 | 2022-02-03 | 学校法人近畿大学 | 分化誘導剤、分化誘導方法、および、これらに用いられる骨組織分解物の製造方法 |
| WO2017073785A1 (ja) * | 2015-10-30 | 2017-05-04 | 学校法人近畿大学 | 分化誘導剤、分化誘導方法、および、これらに用いられる骨組織分解物の製造方法 |
| US10792394B2 (en) | 2016-06-03 | 2020-10-06 | Lifecell Corporation | Methods for localized modification of tissue products |
| US10814033B2 (en) | 2017-01-30 | 2020-10-27 | Lifecell Corporation | Transglutaminase treated products |
| US10940184B2 (en) | 2017-01-30 | 2021-03-09 | Lifecell Corporation | Tissue matrix materials and enzymatic adhesives |
| US10413634B2 (en) | 2017-01-30 | 2019-09-17 | Lifecell Corporation | Transglutaminase treated products |
| US11724004B2 (en) | 2017-01-30 | 2023-08-15 | Lifecell Corporation | Transglutaminase treated products |
| JPWO2020122198A1 (ja) * | 2018-12-12 | 2020-06-18 | ||
| WO2020122198A1 (ja) * | 2018-12-12 | 2020-06-18 | 学校法人近畿大学 | コラーゲン固形物、コラーゲン固形物の製造方法、生体材料、および、生体外材料 |
| US20220023499A1 (en) * | 2018-12-12 | 2022-01-27 | Kinki University | Collagen solid, method for producing collagen solid, biomaterial, and ex vivo material |
| JP7414284B2 (ja) | 2018-12-12 | 2024-01-16 | 学校法人近畿大学 | コラーゲン固形物、コラーゲン固形物の製造方法、生体材料、および、生体外材料 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003211379A8 (en) | 2004-03-19 |
| AU2003211379A1 (en) | 2004-03-19 |
| JPWO2004020470A1 (ja) | 2005-12-15 |
| JP4490268B2 (ja) | 2010-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4490268B2 (ja) | システインプロテアーゼ処理コラーゲンの製造方法およびシステインプロテアーゼ処理コラーゲン | |
| CA2277896C (en) | Preparation of collagen | |
| US7781158B2 (en) | Method of separating collagen from the various animal tissues for producing collagen solution and product using the same | |
| AU2003229362B9 (en) | Collagen and method for producing same | |
| US8338375B2 (en) | Packaged product | |
| Berillis | Marine collagen: Extraction and applications | |
| US20030203008A1 (en) | Preparation of collagen | |
| CN102924731B (zh) | 一种三重交联的胶原蛋白及制造方法和用途 | |
| Pires Figueiredo et al. | Review of collagen type I-based hydrogels: focus on composition-structure-properties relationships | |
| JP2903182B2 (ja) | コラーゲン類、その製造方法及び化粧品 | |
| US7192926B2 (en) | Use of recombinant gelatin-like proteins as plasma expanders and compositions suitable for plasma substitution | |
| Pozzolini et al. | Marine Collagen and its Biotechnological Applications | |
| CN119390816A (zh) | 一种新型重组人源化胶原蛋白水凝胶制备方法 | |
| CN113462736A (zh) | 从猪皮中获取去端肽胶原蛋白的制备方法及胶原蛋白 | |
| KR102623698B1 (ko) | 키토산-콜라겐 고분자 복합체 및 이의 제조방법 | |
| RU2433828C1 (ru) | Инъекционный гетерогенный биополимерный гидрогель для заместительной и регенеративной хирургии и способ его получения | |
| Dhara et al. | Processing and Industrial Aspects of Fish‐scale Collagen: A Biomaterials Perspective | |
| JP2721941B2 (ja) | 天然型強化コラーゲン線維膜及びその調整法 | |
| JP4609897B2 (ja) | コラーゲン組成物、及びその製造方法 | |
| CN117442780A (zh) | 一种重组角蛋白可注射凝胶及其制备方法 | |
| Germany | Other grades of this product | |
| AU2005201970A1 (en) | Collagen and method for producing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2004532678 Country of ref document: JP |
|
| 122 | Ep: pct application non-entry in european phase |